Low-dose cytarabine combined with thalidomide for adults with newly diagnosed LCH

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults aged 18–70 with newly diagnosed multisystem or single-system multifocal LCH who have not received prior systemic therapy will receive induction cycles of cytarabine 100 mg/m² daily on days 1–5 plus thalidomide 100 mg daily on days 1–35 every 35 days for up to 12 cycles. Patients completing induction move to maintenance thalidomide 100 mg daily given on a 28-day cycle for up to 12 cycles. The phase 2, single-arm protocol monitors safety, response, and tolerability with regular clinical and laboratory assessments. Patients with CNS involvement, single-lesion disease, recent major surgery or radiotherapy, or significant cardiac issues are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clearly diagnose and treat adult patients with multisystem or single-system multifocal LCH;
* Aged between 18 and 70 years;
* Multisystem involvement or single-system multifocal disease;
* No prior systemic treatment (patients who have only received local radiotherapy or surgery may be enrolled);
* ECOG performance status score ≤ 2;
* Judged by clinicians as suitable for treatment with this protocol;
* Patients or their families able to understand the study protocol and willing to participate in the study, providing written informed consent.

Exclusion Criteria:

* Patients with LCH involving the central nervous system;
* Single-system single-lesion LCH;
* Subjects who have undergone major surgery within 4 weeks prior to the first dose in the study;
* Subjects who have received radiotherapy within 4 weeks prior to the first dose in the study; subjects with a history of myocardial infarction within the past year;
* Patients with New York Heart Association (NYHA) class 3 or 4 congestive heart failure, or a history of NYHA class 3 or 4 congestive heart failure;
* Pregnant or lactating women;
* Abnormal liver and kidney function: creatinine level ≥176.8μmol/l (2mg/dl), transaminase and bilirubin levels more than 2 times the upper limit of normal (for LCH patients with liver involvement, bilirubin levels more than 10 times the upper limit of normal);
* Abnormal blood counts: absolute neutrophil count less than 1×10\^9/L, platelet count less than 50×10\^9/L;
* Patients or their families unable to understand the conditions and objectives of this study;
* Any other circumstances in which the investigator deems the patient unsuitable to participate in this trial.

Where it's running

• Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, China Recruiting

Study contacts

• Study coordinator: Xinxin XX Cao, doctor
• Email: caoxinxin@126.com
• Phone: +86-18618315968

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted treatment for Langerhans Cell Histiocytosis using trametinib

  This study is testing if trametinib, a new targeted therapy, can help children with Langerhans Cell Histiocytosis feel better and avoid the harsh side effects of traditional chemotherapy.

  Recruiting Phase 2 Cook Children's Health Care System · Fort Worth, Texas · NCT06582745

• Evaluating FCN-159 for treating pediatric patients with recurrent LCH

  This study is testing a new medication called FCN-159 to see if it can help children aged 2 to 16 with recurring Langerhans cell histiocytosis feel better.

  Recruiting at 2 sites Phase 2 Fosunpharma · Beijing, Beijing Municipality and 10 other locations · NCT05997602

• Follow-up on health outcomes in patients with histiocytic disorders

  This study looks at the long-term health effects of histiocytic disorders on around 6000 patients to see how these conditions impact their overall well-being and quality of life.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT05915208

• Using cobimetinib to treat refractory Langerhans cell histiocytosis and other histiocytic disorders

  This study is testing if a drug called cobimetinib can help people with hard-to-treat Langerhans cell histiocytosis and other similar disorders feel better.

  Recruiting at 10 sites Phase 2 Baylor College of Medicine · Phoenix, Arizona and 11 other locations · NCT04079179

• Comparing vinblastine/prednisone and cytarabine for treating Langerhans Cell Histiocytosis

  This study is testing whether a combination of vinblastine and prednisone works better than cytarabine alone for treating Langerhans Cell Histiocytosis in kids and young adults.

  Recruiting at 10 sites Phase 3 Baylor College of Medicine · Palo Alto, California and 10 other locations · NCT02670707

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.